Eli Lilly receives DoJ subpoena over COVID-19 drug manufacturing plant

Eli Lilly and Co said on Thursday it had received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab. The subpoena requested certain documents relating to its site in Branchburg, New Jersey, and the company is cooperating with the investigation, Eli Lilly said. It did not specify what documents the subpoena requested. Reuters reported earlier this month that the company's employees have accused a factory executive of altering documents required by government regulators to downplay serious quality control problems at the Branchburg site.